Oncomed Pharma (OMED) 12.57 $OMED OncoMed Management to

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Oncomed Pharma (OMED) 12.57 $OMED

OncoMed Management to Present at Two Upcoming Investment Conferences
GlobeNewswire - Mon Jun 06, 7:00AM CDT
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, including anti-cancer stem cell and immuno-oncology product candidates, today announced that company management will participate in the following upcoming investor conferences:
OMED: 12.57 (+0.44)

OncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and Lung Cancer at the 2016 ASCO Annual Meeting
GlobeNewswire - Sun Jun 05, 8:00AM CDT
First Presentation of Combination Data for Wnt Inhibitors, Ipafricept and Vantictumab
OMED: 12.57 (+0.44)

OncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:04PM CDT
OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT
OMED: 12.57 (+0.44)

Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 51.35 (-1.06), OMED: 12.57 (+0.44), LGND: 137.72 (+2.84), ANIK: 51.80 (+1.88)

Nektar (NKTR) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:06PM CDT
Nektar (NKTR) reported a narrower-than-expected loss of 14 cents in the first quarter on revenues of $58.9 million.
OMED: 12.57 (+0.44), AZN: 33.91 (-0.23), BXLT: 46.02 (-0.18), NKTR: 17.79 (+0.50)

Illumina (ILMN) Misses on Q1 Earnings, Lowers '16 Guidance
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:33AM CDT
Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 71 cents in the first quarter of 2016.
CBM: 51.35 (-1.06), OMED: 12.57 (+0.44), ANIP: 61.15 (+0.55), ILMN: 169.58 (+3.23)

OncoMed Pharmaceuticals to Report Financial Results for the First Quarter 2016 on Thursday, May 5, 2016
GlobeNewswire - Fri Apr 29, 7:30AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, including anti-cancer stem cell and immuno-oncology product candidates, will announce financial results for the quarter ended March 31, 2016 on Thursday, May 5, 2016. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review first quarter results and recent corporate events beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
OMED: 12.57 (+0.44)

Intellia Therapeutics Appoints Perry Karsen as Chairman of Its Board of Directors
BusinessWire - Fri Apr 22, 4:00PM CDT
Intellia Therapeutics, Inc., a leading gene-editing company, has named Perry Karsen as the Chairman of its Board of Directors.
VYGR: 14.81 (+0.07), OMED: 12.57 (+0.44), GSK: 45.24 (+0.17), BMY: 75.90 (+1.09), CELGZ: 1.13 (-0.03)

OncoMed Announces Clinical Data to be Presented at the 2016 ASCO Annual Meeting
GlobeNewswire - Thu Apr 21, 3:27PM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced today it will present data from several clinical programs at the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting being held June 3-7, 2016 in Chicago, IL.
OMED: 12.57 (+0.44)

OncoMed Presents Biomarker Research for Two Clinical Programs and Demcizumab Mechanism Data at the AACR Annual Meeting 2016
GlobeNewswire - Wed Apr 20, 7:30AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new biomarker research associated with its clinical programs for anti-RSPO3 (OMP-131R10) and vantictumab (anti-FZD7, OMP-18R5), as well as new preclinical mechanism-of-action data for demcizumab (anti-DLL4, OMP-18M21), at the American Association of Cancer Research (AACR) Meeting. All three presentations support ongoing clinical trials: anti-RSPO3 in a Phase1a/b trial in advanced solid tumor and colorectal cancer; vantictumab in a Phase 1b trial in pancreatic cancer; and demcizumab in a Phase 2 randomized study in first-line non-small cell lung cancer (NSCLC).
OMED: 12.57 (+0.44)

OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 8:00AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new data related to its GITRL-Fc immuno-oncology therapeutic candidate at the American Association of Cancer Research (AACR) Meeting. OncoMed plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its GITRL-Fc candidate in late 2016/early 2017.
OMED: 12.57 (+0.44)

OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and Pembrolizumab (anti-PD1)
GlobeNewswire - Thu Mar 17, 7:30AM CDT
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced dosing of the first patient in its Phase 1b clinical trial of OncoMed's investigational agent demcizumab (anti-DLL4, OMP-21M18), with Merck's anti-Programmed Cell Death 1 (PD1) therapy pembrolizumab (KEYTRUDA(R)). The combination of these agents may act as a double blockade for cancer-induced immune suppression with potential application to a number of solid tumor cancers.
OMED: 12.57 (+0.44)

OncoMed to Present Data at the American Association of Cancer Research Annual Meeting 2016
GlobeNewswire - Wed Mar 16, 3:30PM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and immuno-oncology therapeutic candidates in a total of five presentations at the upcoming American Association of Cancer Research (AACR) Meeting to be held April 16-20, 2016 in New Orleans, LA.
OMED: 12.57 (+0.44)

Why OncoMed Pharmaceuticals (OMED) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Mon Feb 01, 7:45AM CST
OncoMed Pharmaceuticals (OMED) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
OMED: 12.57 (+0.44)

OncoMed Tanks on Phase II Pancreatic Cancer Study Update
Zacks Equity Research - Zacks Investment Research - Wed Jan 27, 1:30PM CST
OncoMed Pharmaceuticals' (OMED) shares plunged 45% after it provided disappointing update on its pancreatic cancer candidate tarextumab.
OMED: 12.57 (+0.44), BXLT: 46.02 (-0.18), GSK: 45.24 (+0.17), ANIK: 51.80 (+1.88)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of OncoMed Pharmaceuticals, Inc.
BusinessWire - Mon Jan 25, 12:36PM CST
Levi & Korsinsky announces it has commenced an investigation of OncoMed Pharmaceuticals, Inc. (NASDAQGS: OMED) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
OMED: 12.57 (+0.44)

Why OncoMed Pharmaceuticals' Stock Crashed Today
George Budwell, The Motley Fool - Motley Fool - Mon Jan 25, 11:53AM CST
What : Shares of  OncoMed Pharmaceuticals , a clinical-stage biotech, dropped by more than 46% today on heavy volume after an independent data safety monitoring board reported that the company's midstage pancreatic cancer drug, tarextumab, doesn't...
OMED: 12.57 (+0.44), GSK: 45.24 (+0.17)

Will 2016 Be Celgene Corporation's Best Year Yet?
Sean Williams, The Motley Fool - Motley Fool - Mon Jan 25, 9:38AM CST
Image source: NIH Image Gallery via Flickr. In a year in which the stock market was relatively flat, biotech blue-chip Celgene was a noted outperformer, having gained 5.5% over the 12 months. 2015 was yet another strong year of growth for the...
OMED: 12.57 (+0.44), CELG: 114.57 (+2.38)

OncoMed Provides Update on Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial
GlobeNewswire - Mon Jan 25, 6:30AM CST
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced an update on the Phase 2 ALPINE clinical trial following a pre-planned January 23 interim efficacy assessment of the clinical trial by an independent data safety monitoring board (DSMB). The DSMB assessed data from 172 patients treated as of a January 6, 2016 data cutoff date.
OMED: 12.57 (+0.44)

OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the Gastrointestinal Cancers Symposium
GlobeNewswire - Fri Jan 22, 7:30AM CST
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced updated survival data from the company's Phase 1b clinical trial of demcizumab (anti-DLL4, OMP-21M18) at the Gastrointestinal Cancers Symposium.
OMED: 12.57 (+0.44)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 105

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 228

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 13

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 29

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 28

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 60

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 47

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
2GenPen's Patent Push: Transforming Credit Analysis

Updated Category News Views 7

Changing the Game in Credit Analysis When you hear about a company snagging a patent, it's usually a big whoop-de-do; but 2GenPen's latest achievement is making some serious waves. This isn't some 'pat-yourself-on-the-back' sort of news – it's got teeth in the world of finance. These folks just locked down their second U.S. patent, number 12,784,096, and it's all about...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 131

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Innovation: Schneider Electric's Climate Tech Event

Updated Category News Views 170

Exploring the Excitement of the Climate Tech in the City Event The Climate Tech in the City event embodies the spirit of innovation, uniting key players in the climate technology sector. Leading organizations like Schneider Electric are at the forefront, showcasing groundbreaking advancements and sustainable practices. This year's gathering promises a vibrant day filled...

Continue Reading
Ouster Transforms Chattanooga into a Smart Traffic Hub

Updated Category News Views 404

Ouster's Groundbreaking Initiative in Smart Traffic Management In a significant development for urban traffic management, Ouster, Inc. (NASDAQ: OUST), recognized for its state-of-the-art lidar sensors, has launched a transformative project in Chattanooga. This venture stands out as the largest lidar-enabled traffic system in the United States, boasting a remarkable...

Continue Reading
Bicara Therapeutics Business Highlights and Q1 2025 Financial Review

Updated Category News Views 520

Bicara Therapeutics Announces Key Developments and Q1 2025 Financial Results Latest data from ongoing clinical trials to be showcased at upcoming conferences. Strong financial position enables sustained development through 2029. Bicara Therapeutics Inc. (Nasdaq: BCAX), a pioneering clinical-stage biopharmaceutical firm, focuses on delivering groundbreaking bifunctional...

Continue Reading
IO Biotech Gears Up for December Conferences: Insights and Highlights

Updated Category News Views 148

IO Biotech Prepares for Key Investor Conferences IO Biotech, a trailblazer in developing groundbreaking immune-modulatory cancer vaccines, is set to join two prominent investor events this December. The company, listed under NASDAQ: IOBT, is known for its innovative approach in the biopharmaceutical industry, particularly in creating off-the-shelf therapeutic cancer...

Continue Reading
Cardinal Energy Secures $40 Million Through Latest Debenture Offering

Updated Category News Views 267

Cardinal Energy Ltd. Announces a Major Offering Cardinal Energy Ltd. is excited to inform investors about its latest initiative aimed at raising funds through a significant offering. The company has entered into an agreement with a selected group of underwriters who will help facilitate the sale of $40 million in senior subordinated unsecured debentures. This strategic...

Continue Reading